Roche Holding AG Debt to Equity Ratio 2010-2024 | RHHBY
Current and historical debt to equity ratio values for Roche Holding AG (RHHBY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Roche Holding AG debt/equity for the three months ending December 31, 2024 was 0.85.
| Roche Holding AG Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-12-31 |
$74.56B |
$41.08B |
1.82 |
| 2024-06-30 |
$69.56B |
$36.35B |
1.91 |
| 2023-12-31 |
$63.72B |
$37.05B |
1.72 |
| 2023-06-30 |
$60.10B |
$33.76B |
1.78 |
| 2022-12-31 |
$58.83B |
$33.55B |
1.75 |
| 2022-06-30 |
$59.85B |
$29.98B |
2.00 |
| 2021-12-31 |
$69.99B |
$31.01B |
2.26 |
| 2021-06-30 |
$49.55B |
$44.19B |
1.12 |
| 2020-12-31 |
$49.45B |
$42.42B |
1.17 |
| 2020-06-30 |
$47.27B |
$36.13B |
1.31 |
| 2019-12-31 |
$47.53B |
$36.10B |
1.32 |
| 2019-06-30 |
$49.07B |
$30.95B |
1.59 |
| 2018-12-31 |
$49.23B |
$31.05B |
1.59 |
| 2018-06-30 |
$48.74B |
$30.61B |
1.59 |
| 2017-12-31 |
$48.45B |
$29.48B |
1.64 |
| 2017-06-30 |
$47.29B |
$25.67B |
1.84 |
| 2016-12-31 |
$51.19B |
$26.81B |
1.91 |
| 2016-06-30 |
$55.07B |
$21.73B |
2.54 |
| 2015-12-31 |
$54.60B |
$24.25B |
2.25 |
| 2015-06-30 |
$52.79B |
$20.42B |
2.59 |
| 2014-12-31 |
$59.18B |
$23.59B |
2.51 |
| 2014-06-30 |
$47.80B |
$21.92B |
2.18 |
| 2013-12-31 |
$44.18B |
$22.93B |
1.93 |
| 2013-06-30 |
$46.00B |
$17.06B |
2.70 |
| 2012-12-31 |
$51.30B |
$17.85B |
2.87 |
| 2012-06-30 |
$50.84B |
$12.92B |
3.94 |
| 2011-12-31 |
$53.33B |
$16.40B |
3.25 |
| 2011-06-30 |
$51.08B |
$12.46B |
4.10 |
| 2010-12-31 |
$47.43B |
$11.21B |
4.23 |
| 2010-06-30 |
$50.67B |
$7.05B |
7.19 |
| 2009-12-31 |
$60.17B |
$8.70B |
6.92 |
| 2009-06-30 |
$65.94B |
$3.04B |
21.73 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharma |
$262.006B |
$68.726B |
|
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
|
